COMPUTERIZED BLOOD DONOR PROCESSING SYSTEM

Talisman的长期目标是开发一个完全集成的自动化献血者处理系统，该系统将成为质量，安全性和成本效益的行业标准。第二阶段研究的目标是：1)将Talisman目前的多媒体互动视频献血者健康史筛查系统扩展为一个完全集成的自动化献血者处理系统；2)在三个血液中心成功实施该系统；3)评估该系统的商业潜力；4)评估其社会影响。研究设计和方法涉及顺序设计、开发、测试和验证基于计算机的模块，用于从登记到筛选和结帐的所有捐赠者处理功能。这项研究包括分析献血者、工作人员和管理人员对该系统的反应，确定该系统的净成本效益，评估其国内和国外商业潜力，以及评估该系统加强血液安全和增加血液供应的能力。该研究最具创新性的方面是开发和验证了一系列决策算法，这些算法基于捐赠者的既往捐赠史、关键健康和行为特征以及小型体检结果等信息来确定捐赠者的适宜性。完成后的系统将解决40%的血库成本和60%的可报告错误。建议的商业应用：美国每年有2500万的血液和血浆捐献，世界范围内的市场是这个数字的三到四倍，这取决于自动化成本节约和潜在实现者如何评估收益，该系统的价值可能达到数千万美元。如果该系统成功地阻止了一次最终导致产品召回的捐赠进入血浆池，那么对制造商的价值可能超过100万美元。

Talisman's long term objective is to develop a fully integrated, automated blood donor processing system that will be the industry standard for quality, safety and cost-effectiveness. Aims of Phase II research are: 1) expand Talisman's current multimedia interactive video donor health history screening system into a fully integrated, automated donor processing system, 2) successfully implement the resultant system in three blood centers, 3) evaluate the system's commercial potential, and 4) assess its societal impacts. Research design and methods involve sequential design, development, testing and validation of computer based modules for all donor processing functions from registration, through screening and checkout. The research includes analysis of donors, staff and management reactions to the system, determination of the system's net cost-benefits, assessment of its domestic and foreign commercial potential, and evaluation of the system's capability of enhancing blood safety and increasing blood availability. The most innovative aspects of the research are the development and validation of a series of decision algorithms for determining donor suitability based on donor information regarding prior donation history, key health and behavioral characteristics, and outcome from a mini physical. The completed system will address 40% of blood banking costs and 60% of reportable errors. PROPOSED COMMERCIAL APPLICATIONS: With 25,000,000 annual US blood and plasma donations, and three or four times this market world wide, depending on automation cost savings and how potential implementers value benefits, the system could be worth tens of millions of dollars. If the system were successful in preventing just one donation that ultimately resulted in a product recall from entering a plasma pool, the value to the manufacturer could be in excess of $1,000,000.